Trial Profile
A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Effect of Topical Recombinant Human Vascular Endothelial Growth Factor (Telbermin) for Induction of Healing of Diabetic Foot Ulcers
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Telbermin (Primary)
- Indications Diabetic foot ulcer
- Focus Therapeutic Use
- Sponsors Genentech
- 01 Feb 2013 New trial record